Psychiatrist targets alternative to Janssen’s depression drug

Pharma News: Patients with treatment-resistant depression are missing out on potentially life-changing treatment with ketamine because of funding and systemic barriers in the health system.

According to a multidisciplinary team of medical researchers, including UNSW Sydney, Black Dog Institute and The George Institute for Global Health, “there is a stark disparity in the accessibility and cost of ketamine-based depression treatments. The patented, intranasal s-enantiomeric ketamine formulation, Janssen’s Spravato, is priced at around $500 to $900 per dose, whereas generic ketamine stands at about $5 to $20 per dose. This high cost has led to Spravato being rejected for public reimbursement three times and thus it remains largely inaccessible for Australian patients.”

A slow-release tablet form of ketamine has shown promise in treating severe depression, offering a potential alternative. Unlike the injectable and nasal spray alternatives that require clinicians to monitor patients for two hours while side effects subside, the slow-release tablet form can be taken safely at home without medical supervision and with negligible side effects.

Led by Professor Paul Glue of University of Otago, researchers from UNSW Sydney and the affiliated Black Dog Institute collaborated with colleagues from other research institutions in Australia and New Zealand to run a randomised-controlled trial testing the effectiveness of ketamine tablets to treat depression compared with placebo.

Patients on the strongest dose of ketamine – at 180mg, taken orally twice a week – had the best results when compared to placebo, the researchers found. In the 180mg group, the average reduction in MADRS score dropped by 14 points from a high of 30. In the placebo group, the average reduction was 8 points. All of the remaining doses of ketamine (120mg, 60mg and 30mg) had slightly better outcomes than placebo.

Professor Colleen Loo, who is clinical psychiatrist and researcher with UNSW and BDI, has previously contributed to research on the injectable and nasal spray versions of ketamine treatment for depression.

“The kind of results we’re seeing look as good as other ways of giving ketamine, and are fascinating for two reasons,” she said.

“First of all, there’s the practical clinical reason that this is a way of administering ketamine to treat depression that’s much easier to give. Rather than having to come to the clinic and have an injection and have medical monitoring for two hours, once or twice a week, this is much more convenient and allows patients to have their treatment at home, making it as convenient as other antidepressant medications.
“It is also possible that some people may respond to one approach to treatment, such as the tablet, while others respond to another, such as the injection, so having more treatment approaches is very useful.”

The second reason is that it challenges some beliefs about how ketamine works in helping people successfully overcome depression.

“There’s one school of thought that says what we call dissociative effects – where you’re feeling a kind of altered reality and perception – are actually integral to the ability to improve the depression with ketamine,” Professor Loo noted.

“And that’s very similar to the psychedelic assisted therapy model that says changing your brain circuit functioning in that very profound way gives you new insights that help you to break out of your way of thinking, and that this acute kind of dissociative altered reality experience is necessary for you to improve.

“But with this tablet form you don’t experience that because only a tiny amount is released into the bloodstream at a time, with ongoing slow release over days, and you don’t experience the dissociation at all, and yet people are improving. So it could be that the theory that you must have these altered reality perceptions to improve may not be correct.”

Professor Loo added, “Douglas Pharmaceuticals, which is the New Zealand company that has produced the drug, still needs to do further studies, and it’s important to note this is not yet approved by the FDA in the US or the TGA here in Australia.

“But if it does get through all those hoops and becomes an approved treatment, it certainly makes it much more convenient, not to mention cheaper, to use ketamine to treat severe depression.”

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.